These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28082426)

  • 1. Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine.
    Selen Alpergin ES; Bolandnazar Z; Sabatini M; Rogowski M; Chiellini G; Zucchi R; Assadi-Porter FM
    Physiol Rep; 2017 Jan; 5(1):. PubMed ID: 28082426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Reprogramming by 3-Iodothyronamine (T1AM): A New Perspective to Reverse Obesity through Co-Regulation of Sirtuin 4 and 6 Expression.
    Assadi-Porter FM; Reiland H; Sabatini M; Lorenzini L; Carnicelli V; Rogowski M; Selen Alpergin ES; Tonelli M; Ghelardoni S; Saba A; Zucchi R; Chiellini G
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29786646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR Metabolomics Show Evidence for Mitochondrial Oxidative Stress in a Mouse Model of Polycystic Ovary Syndrome.
    Selen ES; Bolandnazar Z; Tonelli M; Bütz DE; Haviland JA; Porter WP; Assadi-Porter FM
    J Proteome Res; 2015 Aug; 14(8):3284-91. PubMed ID: 26076986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L; Pasinetti E
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipolytic Effects of 3-Iodothyronamine (T1AM) and a Novel Thyronamine-Like Analog SG-2 through the AMPK Pathway.
    Rogowski M; Bellusci L; Sabatini M; Rapposelli S; Rahman SM; Chiellini G; Assadi-Porter FM
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31434215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome.
    Chang AY; Lalia AZ; Jenkins GD; Dutta T; Carter RE; Singh RJ; Nair KS
    Metabolism; 2017 Jun; 71():52-63. PubMed ID: 28521878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum metabolomics profiling by proton nuclear magnetic resonance spectrometry of the response to single oral macronutrient challenges in women with polycystic ovary syndrome (PCOS) compared with male and female controls.
    Escobar-Morreale HF; Martínez-García MÁ; Insenser M; Cañellas N; Correig X; Luque-Ramírez M
    Biol Sex Differ; 2023 Sep; 14(1):62. PubMed ID: 37736753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α.
    Zhao H; Wang D; Xing C; Lv B; Wang X; He B
    J Steroid Biochem Mol Biol; 2023 May; 229():106265. PubMed ID: 36737028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive urinary metabolomics reveals metabolic profiling of polycystic ovary syndrome and its subtypes.
    Zhou W; Hong Y; Yin A; Liu S; Chen M; Lv X; Nie X; Tan N; Zhang Z
    J Pharm Biomed Anal; 2020 Jun; 185():113262. PubMed ID: 32222648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients.
    Sun L; Hu W; Liu Q; Hao Q; Sun B; Zhang Q; Mao S; Qiao J; Yan X
    J Proteome Res; 2012 May; 11(5):2937-46. PubMed ID: 22428626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
    Wang M; Zhao D; Xu L; Guo W; Nie L; Lei Y; Long Y; Liu M; Wang Y; Zhang X; Zhang L; Li H; Zhang J; Yuan D; Yue L
    Metabolism; 2019 May; 94():47-58. PubMed ID: 30768966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.
    Holte J; Bergh T; Berne C; Lithell H
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):463-71. PubMed ID: 7955457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the serum metabolomics of polycystic ovary syndrome before and after compound oral contraceptive treatment.
    Zhao T; Xiao X; Li L; Zhu J; He W; Zhang Q; Wu J; Wu X; Yuan T
    Front Endocrinol (Lausanne); 2024; 15():1354214. PubMed ID: 38948525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation.
    Hai Y; Zuo L; Wang M; Zhang R; Wang M; Ren L; Yang C; Wang J
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation.
    Braulke LJ; Klingenspor M; DeBarber A; Tobias SC; Grandy DK; Scanlan TS; Heldmaier G
    J Comp Physiol B; 2008 Feb; 178(2):167-77. PubMed ID: 17912534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Novel Lipid Profiles in PCOS: Do Insulin and Androgen Oppositely Regulate Bioactive Lipid Production?
    Li S; Chu Q; Ma J; Sun Y; Tao T; Huang R; Liao Y; Yue J; Zheng J; Wang L; Xue X; Zhu M; Kang X; Yin H; Liu W
    J Clin Endocrinol Metab; 2017 Mar; 102(3):810-821. PubMed ID: 27886515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients.
    Tang L; Yuan L; Yang G; Wang F; Fu M; Chen M; Liu D
    Clin Endocrinol (Oxf); 2019 Oct; 91(4):508-516. PubMed ID: 31271659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D3 regulates steroidogenesis in granulosa cells through AMP-activated protein kinase (AMPK) activation in a mouse model of polycystic ovary syndrome.
    Bakhshalizadeh S; Amidi F; Shirazi R; Shabani Nashtaei M
    Cell Biochem Funct; 2018 Jun; 36(4):183-193. PubMed ID: 29676471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome.
    Rahmani E; Samimi M; Ebrahimi FA; Foroozanfard F; Ahmadi S; Rahimi M; Jamilian M; Aghadavod E; Bahmani F; Taghizadeh M; Memarzadeh MR; Asemi Z
    Mol Cell Endocrinol; 2017 Jan; 439():247-255. PubMed ID: 27619403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxysafflor yellow A exerts beneficial effects by restoring hormone secretion and alleviating oxidative stress in polycystic ovary syndrome mice.
    Luo M; Huang JC; Yang ZQ; Wang YS; Guo B; Yue ZP
    Exp Physiol; 2020 Feb; 105(2):282-292. PubMed ID: 31803965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.